Granules India Limited (NSE: GRANULES)
India
· Delayed Price · Currency is INR
559.50
+14.65 (2.69%)
Nov 22, 2024, 3:30 PM IST
Granules India Revenue
Granules India had revenue of 9.67B INR in the quarter ending September 30, 2024, a decrease of -18.74%. This brings the company's revenue in the last twelve months to 44.78B, down -0.86% year-over-year. In the fiscal year ending March 31, 2024, Granules India had annual revenue of 45.06B, down -0.12%.
Revenue (ttm)
44.78B
Revenue Growth
-0.86%
P/S Ratio
n/a
Revenue / Employee
11.04M
Employees
4,057
Market Cap
135.46B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
Mar 31, 2021 | 32.38B | 6.39B | 24.59% |
Mar 31, 2020 | 25.99B | 3.19B | 14.02% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGranules India News
- 15 days ago - Granules India’s Unit V facility in Andhra Pradesh gets US FDA EIR with NAI status - The Times of India
- 15 days ago - Granules India shares surge 2% after US FDA grants ‘No Action Indicated’ status to Andhra Pradesh facility - Business Upturn
- 15 days ago - Granules India’s Andhra Pradesh facility receives ‘No Action Indicated’ status from US FDA - Business Upturn
- 17 days ago - Granules India Q2 FY25 Results: Revenue drops 19%, Net Profit declines 5% YoY - Business Upturn
- 17 days ago - Granules India Q2 FY25 results: Stock jumps 2% ahead of result announcement - Business Upturn
- 4 weeks ago - Stocks to Buy This Diwali: Granules India – Share India recommends with a target of ₹770, potential upside 26% - Business Upturn
- 5 weeks ago - Granules India gets USFDA approval for Bupropion Hydrochloride Extended-Release tablets - Business Upturn
- 7 weeks ago - F&O Ban List for October 4: Granules India, Manappuram Finance, Bandhan Bank and more - Business Upturn